Acurx Pharmaceuticals

Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing new antibiotics for difficult-to-treat infections. The company's approach is to develop candidate antibiotics targeting the DNA polymerase IIIC enzyme, with a research and development pipeline that includes early-stage candidates targeting other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococcus (VRE), and Penicillin-resistant Streptococcus pneumoniae (PRSP).